請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28193
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡錦華 | |
dc.contributor.author | Tze-Jiun Tsai | en |
dc.contributor.author | 蔡澤濬 | zh_TW |
dc.date.accessioned | 2021-06-13T00:02:28Z | - |
dc.date.available | 2012-08-08 | |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-30 | |
dc.identifier.citation | Burkitt RT. Hydronephrosis; a clinical appraisal. Practitioner 180, 449-54 (1958).
Epstein MA, Achong BG and Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 15, 702-3 (1964). Henle G & Henle W. Studies on cell lines derived from Burkitt's lymphoma. Trans N Y Acad Sci 29, 71-9 (1966). Henle W. Evidence for viruses in acute leukemia and Burkitt's tumor. Cancer 21, 580-6 (1968). Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol. 16, 7098-108 (1996). Callan MF, Steven N, Krausa P, Wilson JD, Moss PA, Gillespie GM, Bell JI, Rickinson AB, McMichael AJ. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med. 2,906-11 (1996). Henle W & Henle G. The relation between the Epstein-Barr virus and infectious mononucleosis, Burkitt's lymphoma and cancer of the postnasal space. East Afr Med J 46, 402-6 (1969). Weiss LM, Movahed LA, Warnke RA & Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320, 502-6 (1989). zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P & Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-8 (1970). Labrecque LG, Barnes DM, Fentiman IS, Griffin BE. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res. 55,39-45 (1995). Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 140,769-74 (1992). Rickinson AB, Kieff E. Epstein-Barr virus. Fields Virology, 74, 2397-446 (1996). Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-11 (1984). zur Hausen H, O'Neill FJ, Freese UK, Hecker E. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272, 373-5 (1978). Luka J, Kallin B, Klein G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology. 94, 228-31 (1979). Chang LK, Liu ST. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res. 28, 3918-25 (2000). Tovey MG, Lenoir G, Begon-Lours J. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276, 270-2 (1978). Chevallier-Greco A, Manet E, Chavrier P, Mosnier C, Daillie J, Sergeant A. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5, 3243-9 (1986). Countryman J, Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A. 82, 4085-9 (1985). Countryman J, Jenson H, Seibl R, Wolf H, Miller G. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol. 61, 3672-9 (1987). Zhang CX, Decaussin G, de Turenne Tessier M, Daillie J, Ooka T. Identification of an Epstein-Barr virus-specific desoxyribonuclease gene using complementary DNA. Nucleic Acids Res. 25, 2707-17 (1987). Littler E, Arrand JR. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J Virol. 62, 3892-5 (1988). Goodman SR, Prezyna C, Clough W. Identification and partial purification of two EBV-associated DNA polymerases. IARC Sci Publ. 24, 395-405 (1978). Kallin B, Sternas L, Saemundssen AK, Luka J, Jornvall H, Eriksson B, Tao PZ, Nilsson MT, Klein G. Purification of Epstein-Barr virus DNA polymerase from P3HR-1 cells. J Virol. 54, 561-8 (1985). Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A. 90, 8479-83 (1993). AC. Newton. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 101, 2353-64 (2001). Review. Flemington E, Speck SH. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol. 64, 1217-26 (1990). Kraus RJ, Mirocha SJ, Stephany HM, Puchalski JR, Mertz JE. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus. J Virol. 75, 867-77 (2001). Kraus RJ, Perrigoue JG, Mertz JE. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J Virol. 77, 199-207 (2003). Liu S, Liu P, Borras A, Chatila T, Speck SH. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 16, 143-53 (1997). Gruffat H, Manet E, Sergeant A. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 3, 141-6 (2002). Borras AM, Strominger JL, Speck SH. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J Virol. 70, 3894-901 (1996). Liu S, Borras AM, Liu P, Suske G, Speck SH. Binding of the ubiquitous cellular transcription factors Sp1 and Sp3 to the ZI domains in the Epstein-Barr virus lytic switch BZLF1 gene promoter. Virology. 228, 11-8(1997). Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J, Kenney S. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol. 1224-33 (2000). Lazdins J, Zompetta C, Grimaldi S, Barile G, Venanzoni M, Frati L, Faggioni A. TPA induction of Epstein-Barr virus early antigens in Raji cells is blocked by selective protein kinase-C inhibitors. Int J Cancer. 40, 846-9 (1987). Gao X, Ikuta K, Tajima M, Sairenji T. 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-κB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase. Virology. 286, 91-9 (2001). Daibata M, Speck SH, Mulder C, Sairenji T. Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells. Virology. 198, 446-54 (1994). Takai Y, Kishimoto A, Inoue M, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem. 252, 7603-9 (1977). Bell RM, Hannun YA, Loomis CR. Mechanism of regulation of protein kinase C by lipid second messengers. Symp Fundam Cancer Res. 39, 145-56 (1986). Puls A, Schmidt S, Grawe F and Stabel S. Interaction of protein kinase C with ZIP, a novel protein kinase C-binding protein. Proc. Natl Acad. Sci. USA 94, 6191–6 (1997). Deutsch E, Cohen A, Kazimirsky G, Dovrat S, Rubinfeld H, Brodie C, Sarid R. Role of protein kinase Cδ in reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol. 78, 10187-92 (2004). Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. The structure, expression, and properties of additional members of the protein kinase C family. J Biol Chem. 263, 6927-32 (1988). Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, et al. Proteolytic activation of protein kinase Cδ by an ICE-like protease in apoptotic cells. EMBO J. 14, 6148-56 (1995). Mizuno K, Noda K, Araki T, Imaoka T, Kobayashi Y, Akita Y, Shimonaka M, Kishi S, Ohno S. The proteolytic cleavage of protein kinase C isotypes, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. Eur J Biochem. 250, 7-18 (1997). Takahashi M, Mukai H, Toshimori M, Miyamoto M, Ono Y. Proteolytic activation of PKN by caspase-3 or related protease during apoptosis. Proc Natl Acad Sci U S A. 95, 11566-71 (1998). Watanabe T, Ono Y, Taniyama Y, Hazama K, Igarashi K, Ogita K, Kikkawa U, Nishizuka Y. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-delta subspecies. Proc Natl Acad Sci U S A. 89, 10159-63 (1992). Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, Blumberg PM, Pierce JH, Mushinski JF. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem. 268, 6090-6 (1993). kumoto S, Nishizawa Y, Hosoi M, Koyama H, Yamakawa K, Ohno S, Morii H. Protein kinase C delta inhibits the proliferation of vascular smooth muscle cells by suppressing G1 cyclin expression.J Biol Chem. 272, 13816-22 (1997). Soh JW, Weinstein IB. Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem. 278, 34709-16 (2003). Toyoda M, Gotoh N, Handa H, Shibuya M. Involvement of MAP kinase-independent protein kinase C signaling pathway in the EGF-induced p21(WAF1/Cip1) expression and growth inhibition of A431 cells. Biochem Biophys Res Commun. 250, 430-5 (1998). Li W, Jiang YX, Zhang J, Soon L, Flechner L, Kapoor V, Pierce JH, Wang LH. Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation. Mol Cell Biol. 18, 5888-98 (1998). Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem. 277, 22558-65 (2002). Ghayur T, Hugunin M, Talanian RV, Ratnofsky S, Quinlan C, Emoto Y, Pandey P, Datta R, Huang Y, Kharbanda S, Allen H, Kamen R, Wong W, Kufe D. Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med. 184, 2399-404 (1996). Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V, Bharti A, Kufe D. p73β is regulated by protein kinase Cδ catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem. 277, 33758-65 (2002). Majumder PK, Pandey P, Sun X, Cheng K, Datta R, Saxena S, Kharbanda S, Kufe D. Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem. 275, 21793-6 (2000). Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 5, 769-84 (2006). Review. Chen Lf, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science. 293, 1653-7 (2001). Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 307, 269-73 (2005). Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90, 595-606 (1997). Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 408, 377-81 (2000). Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 19, 662-71 (2000). Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell. 5, 319-22 (1975). Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 268, 462-4 (1977). Storz P, Doppler H, Toker A. Protein kinase Cδ selectively regulates protein kinase D-dependent activation of NF-κB in oxidative stress signaling. Mol Cell Biol. 24, 2614-26 (2004). DeVries TA, Neville MC, Reyland ME. Nuclear import of PKCδ is required for apoptosis: identification of a novel nuclear import sequence. EMBO J. 21, 6050-60 (2002). Lin CT, Chan WY, Chen W, Huang HM, Wu HC, Hsu MM, Chuang SM, Wang CC. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest. 68, 716-27 (1993). Gschwendt M, Kittstein W, Marks F. Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine. FEBS Lett. 338, 85-8 (1994). Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 351, 95-105 (2000). Soltoff SP. Rottlerin is a mitochondrial uncoupler that decreases cellular ATP levels and indirectly blocks protein kinase Cδ tyrosine phosphorylation. J Biol Chem. 276, 37986-92 (2001). Blass M, Kronfeld I, Kazimirsky G, Blumberg PM, Brodie C. Tyrosine phosphorylation of protein kinase Cdelta is essential for its apoptotic effect in response to etoposide. Mol Cell Biol. 22, 182-95 (2002). Bharti A, Kraeft SK, Gounder M, Pandey P, Jin S, Yuan ZM, Lees-Miller SP, Weichselbaum R, Weaver D, Chen LB, Kufe D, Kharbanda S. Inactivation of DNA-dependent protein kinase by protein kinase Cδ: implications for apoptosis. Mol Cell Biol. 18, 6719-28 (1998). Kajimoto T, Shirai Y, Sakai N, Yamamoto T, Matsuzaki H, Kikkawa U, Saito N. Ceramide-induced apoptosis by translocation, phosphorylation, and activation of protein kinase Cδ in the Golgi complex. J Biol Chem. 279, 12668-76 (2004). Li L, Lorenzo PS, Bogi K, Blumberg PM, Yuspa SH. Protein kinase Cδ targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector. Mol Cell Biol. 19, 8547-58 (1999). Gomel R, Xiang C, Finniss S, Lee HK, Lu W, Okhrimenko H, Brodie C. The localization of protein kinase Cδ in different subcellular sites affects its proapoptotic and antiapoptotic functions and the activation of distinct downstream signaling pathways. Mol Cancer Res. 5, 627-39 (2007). Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V, Bharti A, Kufe D. p73β is regulated by protein kinase Cδ catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem. 277, 33758-65 (2002). Miska EA, Karlsson C, Landley E, Nielsen S, Pines J, Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 18,5099–107 (1999). Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Nati Acad Sci U S A. 97,4070-5 (2000). Wang QJ. PKD at the crossroads of DAG and PKC signaling. Treads Pharmacol Sci. 27, 317-23 (2006). Review Page K, Li J, Corbit KC, Rumilla KM, Soh JW, Weinstein IB. Regulation of airway smooth muscle cyclin D1 transcription by protein kinase Cδ. Am J Respir Cell Mol Biol 27, 204-13 (2002). Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem. 276,42084-90 (2001). Suh KS, Tatunchak TT, Crutchley JM, Edwards LE, Marin KG, Yuspa SH. Genomic structure and promoter analysis of PKCδ. Genomics 82, 57-67 (2003). Jung EJ, Lee YM, Lee BL, Chang MS, Kim WH. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Cancer Lett. 247, 77-83 (2007). Feng WH, Israel B, Babb-Traub N, Busson P, Kenny SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial tumors. Cancer Res. 62, 1920-6 (2002). Feng WH, Hong G, Delecluse HJ, Kenny SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. 78, 1893-902 (2004). Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem. J. 376, 545-552 (2003). Chatila T, Ho N, Liu P, Liu S, Mosialos G, Kieff E, Speck SH. The Epstein-Barr virus-induced Ca2+/calmodulin-dependent kinase type IV/Gr promotes a Ca(2+)-dependent switch from latency to viral replication. J Virol. 71, 6560-7 (1997). Dolyniuk M, Pritchett R, Kieff E. Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol. 17, 935-49 (1976). Miller IG, El-Guindy A. Regulation of Epstein-Barr virus lytic cycle activation in malignant and nonmalignant disease. J Natl Cancer Inst. 94, 1733-5 (2002). Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9, 484-96 (1995). Mellor H, Parker PJ. The extended protein kinase C superfamily. 332, 281-92 (1998). Ito T, Matsui Y, Ago T, Ota K, Sumimoto H. Novel modular domain PB1 recognizes PC motif to mediate functional protein-protein interactions. EMBO J. 20, 3938-46 (2001). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28193 | - |
dc.description.abstract | EB病毒的生活週期可分為潛伏期及溶裂期兩部份,潛伏期時EB病毒只表現潛伏期基因,且基因體會隨著宿主細胞週期而複製;當EB病毒由潛伏期進入溶裂期時首先會活化BZLF1及BRLF1基因表現,此病毒基因產物可扮演轉活化因子的角色促進其他溶裂期基因表現,使得大量病毒體產生。過去已發現許多刺激會造成EB病毒活化進入溶裂期,包括phorbol ester、抗免疫球蛋白、增加鈣離子通透性、或是組蛋白去乙醯酶抑制劑,關於前三者如何導致EB病毒溶裂期發生已有相當多的研究,但對於組蛋白去乙醯?抑制劑是透過何種機制造成EB病毒溶裂期發生並沒有太多著墨。而在本論文中以西方點墨法透過蛋白質激酶Cδ抑制劑、RNAi、及過度表現無活化型蛋白質激酶Cδ等方式發現蛋白質激酶Cδ在組蛋白去乙醯?抑制劑所誘發之EB病毒溶裂期蛋白表現扮演重要的角色;更進一步的研究顯示組蛋白去乙醯酶抑制劑能夠造成蛋白質激酶Cδ核轉置、酥氨酸505磷酸化增加以及活化片段CF-PKCδ產生的已知之蛋白質激酶Cδ活化標的。而以報導基因檢測發現過度表現蛋白質激酶Cδ會活化EB病毒溶裂期極早期基因BZLF1促進子活性,因此蛋白質激酶Cδ可透過直接或間接的方式調控與BZLF1促進子鍵結之轉錄因子。最後建構不會產生CF-PKCδ以及無法進行核轉置之蛋白質激酶Cδ突變型蛋白表現質體,初步結果顯示完整片段之蛋白質激酶Cδ對於組蛋白去乙醯?抑制劑誘發EB病毒溶裂期訊息傳導較為重要,而無法進行核轉置之蛋白質激酶Cδ則喪失活化EB病毒溶裂期蛋白表現的功能。 | zh_TW |
dc.description.abstract | The life cycle of Epstein-Barr virus (EBV) can be divided into latent and lytic stage. During the latent stage, EBV only express latent genes, and its genome replicates with host normal cell cycle. The switch from latent stage to lytic cycle leads to the expression of two viral genes, BZLF1 and BRLF1. Their protein products have been known to act as transcriptional activators and stimulate other viral lytic genes expression. Activating EBV lytic cycle can be induced by various reagents, including phorbol ester, anti-immunoglobulin, calcium ionophore, and histone deacetylase inhibitor (HDACi). It has been well studied how phorbol ester, anti-immunoglobulin, and calcium ionphore induce BZLF1 gene expression, but the mechanism of HDACi-induced activation of EBV lytic cycle has not been elucidated. In the present study, various tools were utilized to knocken down the ability or the expression level of PKCδ to investigate its role in the HDACi-induced activation of EBV lytic cycle. Upon HDACi treatment, the amount of nuclear PKCδ, the level of threonine 505 phosphorylation, and the production of catalytic fragment PKCδ (CF-PKCδ) were observed to increase. Luciferase reporter assay demonstrated that overexpression PKCδ can stimulate BZLF1 promoter activity. Since rottlerin has little effect on the histone acetylation level on BZLF1 promoter, PKCδ may regulate, directly or indirectly, the activity of transcription factors on BZLF1 promoter. Lastly, we explore the effect of PKCδ mutation on capase-3 cleavage site and nuclear localization signal (NLS). Our preliminary data reveals that the CF-PKCδ production is not required for HDACi-induced activation of EBV lytic cycle, while mutation on PKCδ NLS reduces EBV lytic genes expression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:02:28Z (GMT). No. of bitstreams: 1 ntu-96-R94445103-1.pdf: 3722247 bytes, checksum: 59ddecc1e21bc432749296d2c2d4e27d (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 中文摘要..................................I
英文摘要..................................II 序論........................................1 研究目的..................................10 實驗方法..................................11 實驗材料..................................17 結果........................................26 討論........................................33 圖...........................................36 附圖........................................51 附表........................................56 參考文獻..................................57 | |
dc.language.iso | zh-TW | |
dc.title | 蛋白質激酶Cδ在組蛋白去乙醯酶抑制劑誘發EB病毒溶裂期時所扮演之角色 | zh_TW |
dc.title | Role of PKCδ in HDACi-Induced Epstein-Barr Virus Reactivation | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 董馨蓮,張堯 | |
dc.subject.keyword | 蛋白質激酶,Cδ,EB病毒,組蛋白去乙醯酶,溶裂期, | zh_TW |
dc.subject.keyword | PKCδ,EBV,HDAC,lytic cycle, | en |
dc.relation.page | 67 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 3.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。